» Articles » PMID: 38001981

Hypoxia-Induced Biosynthesis of the Extracellular Matrix Molecules, Perlecan and Fibronectin, Promotes the Growth of Pleomorphic Adenoma Cells In Vitro Models

Overview
Journal Biomedicines
Date 2023 Nov 25
PMID 38001981
Authors
Affiliations
Soon will be listed here.
Abstract

Salivary pleomorphic adenoma is histopathologically characterized by its colorful stroma with myxoid, chondroid, and hyaline appearances, due to enhanced biosynthesis of extracellular matrix (ECM) molecules and poor vascularity. Thus, pleomorphic adenoma cells embedded in the stroma typically survive under hypoxic conditions. We determined the expression kinetics of ECM molecules, such as perlecan and fibronectin (FN), under hypoxia in SM-AP1 cells which are duct epithelial differentiated cells, and in SM-AP4 cells, which are myoepithelial differentiated cells, cloned from pleomorphic adenoma of the parotid gland. We investigated hypoxia-inducible factor-1α (HIF-1α)-inducing pathways through a variety of ECM molecules in association with their cellular proliferation and migration. We observed that hypoxic conditions with elevated HIF-1α protein levels induced increased expression of perlecan and FN in SM-AP cells than in controls. Moreover, perlecan and FN knockdown reduced the proliferation of SM-AP1 and SM-AP4 cells under hypoxia. Further, SM-AP1 cell migration was enhanced by both perlecan and FN knockdown, whereas SM-AP4 cell migration was increased by perlecan knockdown and inhibited by fibronectin knockdown. The results indicated that pleomorphic adenoma cells can survive under hypoxic conditions by promoting cell proliferation via enhanced synthesis of ECM molecules. Overall, ECM molecules may be a new anti-tumor target under hypoxic conditions.

Citing Articles

Putative Biomarkers for Prognosis, Epithelial-to-Mesenchymal Transition, and Drug Response in Cell Lines Representing Oral Squamous Cell Carcinoma Progression.

Hamoui M, Rizvi S, Arnouk H, Roberts C Genes (Basel). 2025; 16(2).

PMID: 40004538 PMC: 11855662. DOI: 10.3390/genes16020209.

References
1.
Livolsi V, Perzin K . Malignant mixed tumors arising in salivary glands. I. Carcinomas arising in benign mixed tumors: a clinicopathologic study. Cancer. 1977; 39(5):2209-30. DOI: 10.1002/1097-0142(197705)39:5<2209::aid-cncr2820390540>3.0.co;2-8. View

2.
Mishra M, Naik V, Kale A, Ankola A, Pilli G . Perlecan (basement membrane heparan sulfate proteoglycan) and its role in oral malignancies: an overview. Indian J Dent Res. 2012; 22(6):823-6. DOI: 10.4103/0970-9290.94678. View

3.
Ribatti D, Solimando A, Pezzella F . The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer. Cancers (Basel). 2021; 13(14). PMC: 8304542. DOI: 10.3390/cancers13143433. View

4.
Maruyama S, Cheng J, Yamazaki M, Liu A, Saku T . Keratinocyte growth factor colocalized with perlecan at the site of capsular invasion and vascular involvement in salivary pleomorphic adenomas. J Oral Pathol Med. 2009; 38(4):377-85. DOI: 10.1111/j.1600-0714.2008.00742.x. View

5.
Maruyama S, Shimazu Y, Kudo T, Sato K, Yamazaki M, Abe T . Three-dimensional visualization of perlecan-rich neoplastic stroma induced concurrently with the invasion of oral squamous cell carcinoma. J Oral Pathol Med. 2014; 43(8):627-36. DOI: 10.1111/jop.12184. View